Oligonucleotide medicines are growing up — and moving beyond rare diseases

What started as an experimental concept is now a bona fide therapeutic class. A comprehensive review published in Cell Reports Medicine traces how antisense oligonucleotides (ASOs) and RNA interference (RNAi) therapies have evolved from lab curiosities into approved treatments for conditions ranging from spinal muscular atrophy to hereditary amyloidosis — and increasingly, common diseases like high cholesterol.

The secret sauce? Smarter chemistry and better delivery. Chemical tweaks to the backbone and sugar of these molecules have dramatically improved their stability and target specificity. On the delivery side, lipid nanoparticles and GalNAc conjugates have made liver-targeted therapies highly effective — though getting oligonucleotides to other tissues like the brain, muscle, and lung remains a significant hurdle.

By the Numbers:

• 21 oligonucleotide therapies have received regulatory approval (2 later withdrawn)
• Inclisiran, a GalNAc-siRNA targeting PCSK9, cut LDL cholesterol by ~50% in phase 3 trials, with effects lasting at least 18 months
• 40+ individualized ASOs have been developed for 80+ patients with ultra-rare diseases

Why it matters: These therapies are no longer just for rare disease patients. As the field pushes into common conditions and explores AI-assisted design and personalized treatments, oligonucleotides could reshape how medicine targets disease at the genetic level — for far more people.